Indoxyl Sulfate-Induced Macrophage Toxicity and Therapeutic Strategies in Uremic Atherosclerosis
Toxins · 31.05.2024 · 16 (6) · 254
DOI: 10.3390/toxins16060254 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Toxins, online erschienen am 31.05.2024. Verfasst von Takuya Wakamatsu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata 951-8510, Japan. Hauptthemen laut MEDLINE: Indican, Atherosclerosis, Macrophages, Uremia. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 164 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Cardiovascular disease (CVD) frequently occurs in patients with chronic kidney disease (CKD), particularly those undergoing dialysis. The mechanisms behind this may be related to traditional risk factors and CKD-specific factors that accelerate atherosclerosis and vascular calcification in CKD patients. The accumulation of uremic toxins is a significant factor in CKD-related systemic disorders. Basic research suggests that indoxyl sulfate (IS), a small protein-bound uremic toxin, is associated with macrophage dysfunctions, including increased oxidative stress, exacerbation of chronic inflammation, and abnormalities in lipid metabolism. Strategies to mitigate the toxicity of IS include optimizing gut microbiota, intervening against the abnormality of intracellular signal transduction, and using blood purification therapy with higher efficiency. Further research is needed to examine whether lowering protein-bound uremic toxins through intervention leads to a reduction in CVD in patients with CKD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata 951-8510, Japan.
- Ohgo Clinic, Maebashi 371-0232, Japan.
ORCID-Profile: Suguru Yamamoto
Zitieren
APA
Wakamatsu, T., Yamamoto, S., Yoshida, S., & Narita, I. (2024). Indoxyl Sulfate-Induced Macrophage Toxicity and Therapeutic Strategies in Uremic Atherosclerosis. Toxins, 16(6), 254. https://doi.org/10.3390/toxins16060254
Vancouver
Wakamatsu T, Yamamoto S, Yoshida S, Narita I. Indoxyl Sulfate-Induced Macrophage Toxicity and Therapeutic Strategies in Uremic Atherosclerosis. Toxins. 2024;16(6):254. doi:10.3390/toxins16060254
BibTeX
@article{Wakamatsu2024,
author = {Wakamatsu, Takuya and Yamamoto, Suguru and Yoshida, Shiori and Narita, Ichiei},
title = {Indoxyl Sulfate-Induced Macrophage Toxicity and Therapeutic Strategies in Uremic Atherosclerosis},
journal = {Toxins},
year = {2024},
volume = {16},
number = {6},
pages = {254},
doi = {10.3390/toxins16060254}
}
EUVIMED